About ImQuest Life Sciences
ImQuest Life Sciences is a Healthcare company based in Frederick (United States) founded in 2005, and was acquired by Cytocom in July 2020. First-in-class drugs for infectious disease, cancer, and inflammation are developed. The company was acqui-hired. ImQuest Life Sciences offers products and services including Domain Sale Service. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
ImQuest Life Sciences discovers and develops first in class drugs for the treatment of infectious disease, cancer and inflammation. Its products in development include IQP-0528, a vaginal gel for the prevention of HIV transmission to women (Phase 1), a topical microbicide to prevent HIV transmission (Preclinical). The company has also early stage programs for hepatitis B, hepatitis C and influenza, cancer. The company has a drug development alliance with Samjin Pharmaceutical of Korea.
- Headquarters Frederick, United States
- Stage Acquired
- SectorsHealthcare
- Website imquestls.com
- Acquired by Cytocom (Jul 2020)
Products & Services of ImQuest Life Sciences
ImQuest Life Sciences offers a comprehensive portfolio of products and services, including Domain Sale Service.
Platform for purchasing domains online quickly
Investors in ImQuest Life Sciences
ImQuest Life Sciences has secured backing from 1 investor. Prominent investors backing the company include Cytocom.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of therapeutic solutions for the treatment of infectious diseases | 2013 | cytocom.com | Winter Park, United States |
Investor details for ImQuest Life Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ImQuest Life Sciences
2 dated milestones of ImQuest Life Sciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded ImQuest Life Sciences is founded.
- Exit Acquired by Cytocom.
Competitors of ImQuest Life Sciences
ImQuest Life Sciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of ImQuest Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as ImQuest Life Sciences (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imquest Life Sciences
Complete news archive for ImQuest Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImQuest Life Sciences
ImQuest Life Sciences was founded in 2005.
ImQuest Life Sciences is headquartered in Frederick, United States. It is registered at Frederick, Maryland, United States.
ImQuest Life Sciences discovers and develops first in class drugs for the treatment of infectious disease, cancer and inflammation. Its products in development include IQP-0528, a vaginal gel for the prevention of HIV transmission to women (Phase 1), a topical microbicide to prevent HIV transmission (Preclinical). The company has also early stage programs for hepatitis B, hepatitis C and influenza, cancer. The company has a drug development alliance with Samjin Pharmaceutical of Korea.
ImQuest Life Sciences's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
ImQuest Life Sciences offers Domain Sale Service.
ImQuest Life Sciences has 1 investor. Key investors include Cytocom.
Yes. ImQuest Life Sciences was acquired by Cytocom in July 2020.

